Bivalirudin Compared to Heparin as the Primary Anticoagulant in Pediatric Berlin Heart Recipients
- 20 March 2023
- journal article
- research article
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (5) , e205-e211
Abstract
Bivalirudin has been used in increasing frequency as an alternative to unfractionated heparin (UFH) in pediatric recipients of Berlin Heart EXCOR ventricular assist devices (VAD). This single-center, retrospective review characterizes anticoagulant trends and outcomes in pediatric Berlin Heart VAD recipients implanted between September 1, 2013, and August 31, 2021, anticoagulated with either bivalirudin or UFH. Thirty-one patients were included; 65% who received bivalirudin and 35% who received UFH. The median age was 2.9 years, included 64.5% females, with 61.3% of patients diagnosed with dilated cardiomyopathy and 25.8% of patients with congenital heart disease. Therapeutic anticoagulation was achieved sooner in the bivalirudin group compared to UFH via anti-Xa monitoring (median 5.7 and 69.5 hours, respectively, p < 0.001). Bivalirudin had a greater number of therapeutic values comparatively to UFH (52% and 24%, respectively; p < 0.001) and a superior number of hours in the therapeutic range (67% and 32%, respectively; p < 0.001). Secondary outcomes were similar among the two groups, apart from greater chest tube output (UFH), more frequent events of elevated plasma-free hemoglobin (bivalirudin), and more frequent elevated inflammatory markers postimplant (bivalirudin). Prevalence of pump replacements secondary to significant clot burden and prevalence of stroke was comparable. In this patient cohort, bivalirudin demonstrated greater anticoagulation stability comparatively to UFH. Multicenter collaboration would be necessary to identify whether this further translates into improved patient outcomes.Keywords
This publication has 31 references indexed in Scilit:
- Steroid Therapy Attenuates Acute Phase Reactant Response Among Children on Ventricular Assist Device SupportThe Annals of Thoracic Surgery, 2015
- Neurological Complications and Outcomes in the Berlin Heart EXCOR ® Pediatric Investigational Device Exemption TrialJournal of the American Heart Association, 2015
- Bivalirudin in Pediatric Patients Maintained on Extracorporeal Life SupportPediatric Critical Care Medicine, 2013
- Antithrombotic strategies in children receiving long-term Berlin Heart EXCOR ventricular assist device therapyThe Journal of Heart and Lung Transplantation, 2013
- Berlin Heart EXCOR Pediatric Ventricular Assist Device for Bridge to Heart Transplantation in US ChildrenCirculation, 2013
- Prospective Trial of a Pediatric Ventricular Assist DeviceNew England Journal of Medicine, 2012
- The profile of the systemic inflammatory response in children undergoing ventricular assist device supportInteractive CardioVascular and Thoracic Surgery, 2012
- Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenationCritical Care, 2011
- Berlin Heart EXCOR Pediatric ventricular assist device Investigational Device Exemption study: Study design and rationaleAmerican Heart Journal, 2011
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009